[Prophylactic influenza vaccination: what is the situation in Germany?].
Identifieur interne : 000468 ( Main/Exploration ); précédent : 000467; suivant : 000469[Prophylactic influenza vaccination: what is the situation in Germany?].
Auteurs : P. Wutzler [Allemagne]Source :
- Deutsche medizinische Wochenschrift (1946) [ 0012-0472 ] ; 2006.
Descripteurs français
- KwdFr :
- Accessibilité des services de santé, Adolescent, Adulte, Adulte d'âge moyen, Allemagne (épidémiologie), Analyse coût-bénéfice, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Facteurs de risque, Femelle, Flambées de maladies (), Grippe humaine (), Grippe humaine (épidémiologie), Humains, Mâle, Nourrisson, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination de masse (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- épidémiologie : Allemagne, Grippe humaine.
- Accessibilité des services de santé, Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Facteurs de risque, Femelle, Flambées de maladies, Grippe humaine, Humains, Mâle, Nourrisson, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination de masse.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Disease Outbreaks (prevention & control), Female, Germany (epidemiology), Health Services Accessibility, Humans, Infant, Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Mass Vaccination (statistics & numerical data), Middle Aged, Risk Factors.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Germany.
- chemical , immunology : Influenza Vaccines.
- epidemiology : Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- statistics & numerical data : Mass Vaccination.
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Female, Health Services Accessibility, Humans, Infant, Male, Middle Aged, Risk Factors.
Abstract
Vaccination is the most efficacious and cost-effective measure for the prevention of influenza. Although the vaccination rate among the population of Germany has been gradually increasing in the last few years, only 40% of chronically ill persons are vaccinated. As a third of all persons aged over 50 years have a chronic disease, vaccination of those aged 50 years and over, from the those recommended 60 years, should be considered. Such a strategy would be cost-effective both for insurance companies and society as a whole. There are at present no data on ambulatory influenza vaccination rates in children, even though this could reduce the high death rate among this age group and decrease the spread of the disease among the general population. At present all children with an underlying disease and all those in immediate contact with them should be vaccinated. Pregnant women whose expected date of delivery falls within the influenza season should also be vaccinated so that they and their newborn child are protected against influenza.
DOI: 10.1055/s-2006-932543
PubMed: 16493571
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Prophylactic influenza vaccination: what is the situation in Germany?].</title><author><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name><affiliation wicri:level="1"><nlm:affiliation>Institut für Virologie und Antivirale Therapie, Universitätsklinikum Jena. Peter.Wutzler@med.uni-jena.de</nlm:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16493571</idno><idno type="pmid">16493571</idno><idno type="doi">10.1055/s-2006-932543</idno><idno type="wicri:Area/Main/Corpus">000497</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000497</idno><idno type="wicri:Area/Main/Curation">000497</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000497</idno><idno type="wicri:Area/Main/Exploration">000497</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Prophylactic influenza vaccination: what is the situation in Germany?].</title><author><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name><affiliation wicri:level="1"><nlm:affiliation>Institut für Virologie und Antivirale Therapie, Universitätsklinikum Jena. Peter.Wutzler@med.uni-jena.de</nlm:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author></analytic><series><title level="j">Deutsche medizinische Wochenschrift (1946)</title><idno type="ISSN">0012-0472</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Disease Outbreaks (prevention & control)</term><term>Female</term><term>Germany (epidemiology)</term><term>Health Services Accessibility</term><term>Humans</term><term>Infant</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Mass Vaccination (statistics & numerical data)</term><term>Middle Aged</term><term>Risk Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Allemagne (épidémiologie)</term><term>Analyse coût-bénéfice</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Femelle</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccination de masse ()</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Mass Vaccination</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Health Services Accessibility</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Femelle</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccination de masse</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vaccination is the most efficacious and cost-effective measure for the prevention of influenza. Although the vaccination rate among the population of Germany has been gradually increasing in the last few years, only 40% of chronically ill persons are vaccinated. As a third of all persons aged over 50 years have a chronic disease, vaccination of those aged 50 years and over, from the those recommended 60 years, should be considered. Such a strategy would be cost-effective both for insurance companies and society as a whole. There are at present no data on ambulatory influenza vaccination rates in children, even though this could reduce the high death rate among this age group and decrease the spread of the disease among the general population. At present all children with an underlying disease and all those in immediate contact with them should be vaccinated. Pregnant women whose expected date of delivery falls within the influenza season should also be vaccinated so that they and their newborn child are protected against influenza.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16493571</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-0472</ISSN><JournalIssue CitedMedium="Print"><Volume>131</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Deutsche medizinische Wochenschrift (1946)</Title><ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation></Journal><ArticleTitle>[Prophylactic influenza vaccination: what is the situation in Germany?].</ArticleTitle><Pagination><MedlinePgn>453-7</MedlinePgn></Pagination><Abstract><AbstractText>Vaccination is the most efficacious and cost-effective measure for the prevention of influenza. Although the vaccination rate among the population of Germany has been gradually increasing in the last few years, only 40% of chronically ill persons are vaccinated. As a third of all persons aged over 50 years have a chronic disease, vaccination of those aged 50 years and over, from the those recommended 60 years, should be considered. Such a strategy would be cost-effective both for insurance companies and society as a whole. There are at present no data on ambulatory influenza vaccination rates in children, even though this could reduce the high death rate among this age group and decrease the spread of the disease among the general population. At present all children with an underlying disease and all those in immediate contact with them should be vaccinated. Pregnant women whose expected date of delivery falls within the influenza season should also be vaccinated so that they and their newborn child are protected against influenza.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wutzler</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut für Virologie und Antivirale Therapie, Universitätsklinikum Jena. Peter.Wutzler@med.uni-jena.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Influenza-Schutzimpfung -- Wo steht Deutschland?</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Med Wochenschr</MedlineTA><NlmUniqueID>0006723</NlmUniqueID><ISSNLinking>0012-0472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16493571</ArticleId><ArticleId IdType="doi">10.1055/s-2006-932543</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16493571
|texte= [Prophylactic influenza vaccination: what is the situation in Germany?].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16493571" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |